Journal CME 34.12: Immunomodulatory drugs alleviate L-DOPA-induced dyskinesia in a rat model of Parkinson’s disease

Be the first to review this product

Availability: In stock

$50.00

Quick Overview

Member price: $0.00


CME Credits: 1

Journal CME 34.12: Immunomodulatory drugs alleviate L-DOPA-induced dyskinesia in a rat model of Parkinson’s disease

Double click on above image to view full picture

Zoom Out
Zoom In

More Views

Details

Thalidomide and closely related analogues are used clinically for their immunomodulatory and antiangiogenic properties mediated by the inhibition of the proinflammatory cytokine tumor necrosis factor α. Neuroinflammation and angiogenesis contribute to classical neuronal mechanisms underpinning the pathophysiology of L-dopa-induced dyskinesia, a motor complication associated with L-dopa therapy in Parkinson’s disease. The efficacy of thalidomide and the more potent derivative 3,60 -dithiothalidomide on dyskinesia was tested in the 6-hydroxydopamine Parkinson’s disease model.

This module will take you approximately 1 hour to complete.

Faculty:

Laura Boi

Augusta Pisanu

Nigel H. Greig

Michael T. Scerba

David Tweedie

Giovanna Mulas

Sandro Fenu

Ezio Carboni

Saturnino Spiga

Anna R. Carta

Product Tags

Use spaces to separate tags. Use single quotes (') for phrases.